M3 Inc

M3: Covid Related Trials and Vaccination Programs Drive Earnings; Core Business Growth Slowing Down

211 Views03 Feb 2022 02:51
m3's 3QFY03/2022 earnings were driven by Covid-related clinical trials and vaccination projects that will come to an end once pandemic ease off. Core business is slowing down and m3 has announced...
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
(Paid Plans Only)